Progress in T cell receptor-gene engineered T cell immunotherapy for solid tumors
10.3781/j.issn.1000-7431.2018.55.696
- Author:
Lanlin ZHANG
1
Author Information
1. Department of Oncology, Fudan University, Shanghai Cancer Center
- Publication Type:Journal Article
- Keywords:
Adoptive;
Antigen;
Immunotherapy;
Receptors;
T cell;
Treatment outcome
- From:
Tumor
2018;38(3):256-263
- CountryChina
- Language:Chinese
-
Abstract:
T cell receptor-gene engineered T cells (TCR-T) therapy is a kind of tumor adoptive immunotherapy based on the modified T cells, which can generate a strong anti-tumor immune effect in vivo by virtue of its high affinity recognition of tumor-specific antigens. Many I/II-phase clinical trials have shown the safety and effectiveness of TCR-T in treatment of solid tumors, especially melanoma and synovial cell sarcoma. However, the clinical immunotherapy of TCR-T cells has also brought some challenges, such as off-target toxicity, cytokine release syndrome and neurotoxicity. It is predicted that the efficacy and safety of TCR-T immunotherapy can be improved by screening for high-affinity TCRs, reducing adverse reactions of TCR-T cell immunotherapy and other ways. And with the deepening of research, TCR-T immunotherapy will bring new hope to the patients with tumor.
